CTL019: Ph II ELIANA data

Top-line data from 50 patients ages 3-21 with relapsed and refractory B cell ALL in the open-label, international Phase II ELIANA trial showed that a single dose of IV CTL019 led to a CR or CRi at 3 months post-infusion in 82% of patients. In patients with complete remission, no MRD was detected and the 6-month estimated relapse-free rate among all responders was 60%. Grade 3/4 cytokine release syndrome (CRS) occurred in 48% of patients. There were no deaths due to CRS. Data were presented at the American Society of Hematology meeting in San Diego...